Division of Endocrinology, Diabetes and Clinical Nutrition, University Hospital Zurich, Switzerland.
Nephrology, Dialysis and Transplantation Unit (Stefoni), S.Orsola-Malpighi Hospital, University of Bologna, Italy.
J Tissue Eng Regen Med. 2017 Jan;11(1):109-120. doi: 10.1002/term.1891. Epub 2014 Apr 16.
Previously we demonstrated the superiority of small islets vs large islets in terms of function and survival after transplantation, and we generated reaggregated rat islets (pseudo-islets) of standardized small dimensions by the hanging-drop culture method (HDCM). The aim of this study was to generate human pseudo-islets by HDCM and to evaluate and compare the physiological properties of rat and human pseudo-islets. Isolated rat and human islets were dissociated into single cells and incubated for 6-14 days by HDCM. Newly formed pseudo-islets were analysed for dimensions, morphology, glucose-stimulated insulin secretion (GSIS) and total insulin content. The morphology of reaggregated human islets was similar to that of native islets, while rat pseudo-islets had a reduced content of α and δ cells. GSIS of small rat and human pseudo-islets (250 cells) was increased up to 4.0-fold (p < 0.01) and 2.5-fold (p < 0.001), respectively, when compared to their native counterparts. Human pseudo-islets showed a more pronounced first-phase insulin secretion as compared to intact islets. GSIS was inversely correlated to islet size, and small islets (250 cells) contained up to six-fold more insulin/cell than large islets (1500 cells). Tissue loss with this new technology could be reduced to 49.2 ± 1.5% in rat islets, as compared to the starting amount. With HDCM, pseudo-islets of standardized size with similar cellular composition and improved biological function can be generated, which compensates for tissue loss during production. Transplantation of small pseudo-islets may represent an attractive strategy to improve graft survival and function, due to better oxygen and nutrient supply during the phase of revascularization. Copyright © 2014 John Wiley & Sons, Ltd.
先前我们已经证明了在移植后的功能和存活率方面,小胰岛比大胰岛具有优势,并且我们通过悬滴培养法(HDCM)生成了标准化小尺寸的重组大鼠胰岛(伪胰岛)。本研究的目的是通过 HDCM 生成人伪胰岛,并评估和比较大鼠和人伪胰岛的生理特性。分离的大鼠和人胰岛被解离成单个细胞,并通过 HDCM 孵育 6-14 天。分析新形成的伪胰岛的尺寸、形态、葡萄糖刺激的胰岛素分泌(GSIS)和总胰岛素含量。重组人胰岛的形态与天然胰岛相似,而大鼠伪胰岛的α和δ细胞含量减少。与天然胰岛相比,小大鼠和人伪胰岛(250 个细胞)的 GSIS 分别增加了 4.0 倍(p<0.01)和 2.5 倍(p<0.001)。与人胰岛相比,人伪胰岛表现出更明显的第一阶段胰岛素分泌。GSIS 与胰岛大小呈负相关,与大胰岛(1500 个细胞)相比,小胰岛(250 个细胞)每个胰岛含有多达六倍的胰岛素。与起始量相比,该新技术可将大鼠胰岛的组织损失减少到 49.2±1.5%。通过 HDCM,可以生成具有相似细胞组成和改善的生物学功能的标准化大小的伪胰岛,这可以补偿生产过程中的组织损失。由于在再血管化阶段有更好的氧气和营养供应,移植小的伪胰岛可能代表一种改善移植物存活和功能的有吸引力的策略。版权所有©2014 年 John Wiley & Sons, Ltd.